Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Malarial dihydrofolate reductase (DHFR) is the target of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of which have been compromised by resistance arising through mutations at various sites on the enzyme. Here, we describe the use of cocrystal structures with inhibitors and substrates, along with efficacy and pharmacokinetic profiling for the design, characterization, and preclinical development of a selective, highly efficacious, and orally available antimalarial drug candidate that potently inhibits both wild-type and clinically relevant mutated forms of Plasmodium falciparum (Pf) DHFR. Important structural characteristics of P218 include pyrimidine side-chain flexibility and a carboxylate group that makes charge-mediated hydrogen bonds with conserved Arg122 (PfDHFR-TS amino acid numbering). An analogous interaction of P218 with human DHFR is disfavored because of three species-dependent amino acid substitutions in the vicinity of the conserved Arg. Thus, P218 binds to the active site of PfDHFR in a substantially different fashion from the human enzyme, which is the basis for its high selectivity. Unlike pyrimethamine, P218 binds both wild-type and mutant PfDHFR in a slow-on/slow-off tight-binding mode, which prolongs the target residence time. P218, when bound to PfDHFR-TS, resides almost entirely within the envelope mapped out by the dihydrofolate substrate, which may make it less susceptible to resistance mutations. The high in vivo efficacy in a SCID mouse model of P. falciparum malaria, good oral bioavailability, favorable enzyme selectivity, and good safety characteristics of P218 make it a potential candidate for further development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Global malaria mortality between 1980 and 2010: a systematic analysis
Murray, C. J., Rosenfeld, L. C., Lim, S. S., Andrews, K. G., Foreman, K. J., Haring, D., Fullman, N., Naghavi, M., Lozano, R., & Lopez, A. D. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60034-8 · Cited by 1,452
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Thousands of chemical starting points for antimalarial lead identification
Gamo, F.-J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.-L., Vanderwall, D. E., Green, D. V. S., Kumar, V., Hasan, S., et al. (2010) · Nature · doi:10.1038/nature09107 · Cited by 996
Implications of protein flexibility for drug discovery
Teague, S. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1129 · Cited by 755 · cited 1×
“Larger conformationally constrained ligands cannot adapt as well to changes in the geometry of the binding site and, as a consequence, are highly susceptible to drug-resistance mutations, often by steric exclusion (23, 24).”
BackgroundCopeland, R. A. (2013) · Wiley eBooks · doi:10.1002/9781118540398 · Cited by 678
Identification of an antimalarial synthetic trioxolane drug development candidate
Vennerstrom, J. L., Arbe-Barnes, S., Brun, R., Charman, S. A., Chiu, F. C. K., Chollet, J., Dong, Y., Dorn, A., Hunziker, D., Matile, H., et al. (2004) · Nature · doi:10.1038/nature02779 · Cited by 622
Self-citationChemical genetics of Plasmodium falciparum
Guiguemde, W. A., Shelat, A. A., Bouck, D., Duffy, S., Crowther, G. J., Davis, P. H., Smithson, D. C., Connelly, M., Clark, J., Zhu, F., et al. (2010) · Nature · doi:10.1038/nature09099 · Cited by 566
Insights into antifolate resistance from malarial DHFR-TS structures
Yuvaniyama, J., Chitnumsub, P., Kamchonwongpaisan, S., Vanichtanankul, J., Sirawaraporn, W., Taylor, P., Walkinshaw, M. D., & Yuthavong, Y. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb921 · Cited by 451
Self-citationPeterson, D. S., Milhous, W. K., & Wellems, T. E. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.3018 · Cited by 419
Charman, S. A., Arbe-Barnes, S., Bathurst, I. C., Brun, R., Campbell, M., Charman, W. N., Chiu, F. C. K., Chollet, J., Craft, J. C., Creek, D. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015762108 · Cited by 373
Self-citationAntifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase
Sirawaraporn, W., Sathitkul, T., Sirawaraporn, R., Yuthavong, Y., & Santi, D. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1124 · Cited by 341
Self-citationDihydrofolate Reductase: X-ray Structure of the Binary Complex with Methotrexate
Matthews, D. A., Alden, R. A., Bolin, J. T., Freer, S. T., Hamlin, R., Xuong, N., Kraut, J., Poe, M., Williams, M., & Hoogsteen, K. (1977) · Science · doi:10.1126/science.17920 · Cited by 322
Self-citationNew medicines to improve control and contribute to the eradication of malaria
Wells, T. N. C., Alonso, P. L., & Gutteridge, W. E. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2972 · Cited by 298
Stepwise acquisition of pyrimethamine resistance in the malaria parasite
Lozovsky, E. R., Chookajorn, T., Brown, K. M., Imwong, M., Shaw, P. J., Kamchonwongpaisan, S., Neafsey, D. E., Weinreich, D. M., & Hartl, D. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905922106 · Cited by 280
Self-citationStructure of and kinetic channelling in bifunctional dihydrofolate reductase–thymidylate synthase
Knighton, D. R., Kan, C.-C., Howland, E., Janson, C. A., Hostomska, Z., Welsh, K. M., & Matthews, D. A. (1994) · Nature Structural Biology · doi:10.1038/nsb0394-186 · Cited by 196
Self-citationRomano, K. P., Ali, A., Royer, W. E., & Schiffer, C. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006370107 · Cited by 189
The State of the Art in Anti-Malarial Drug Discovery and Development
Burrows, J. N., Chibale, K., & Wells, T. N. C. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795429194 · Cited by 174
The Global Portfolio of New Antimalarial Medicines Under Development
Olliaro, P., & Wells, T. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.51 · Cited by 168
Targeting enzyme inhibitors in drug discovery
Copeland, R. A., Harpel, M. R., & Tummino, P. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.7.967 · Cited by 152
Combating Susceptibility to Drug Resistance
King, N. M., Prabu-Jeyabalan, M., Nalivaika, E. A., & Schiffer, C. A. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.08.010 · Cited by 150
Molecular Basis for Drug Resistance in HIV-1 Protease
Ali, A., Bandaranayake, R. M., Cai, Y., King, N. M., Kolli, M., Mittal, S., Foulkes-Murzycki, J. E., Nalam, M. N. L., Nalivaika, E. A., Özen, A., et al. (2010) · Viruses · doi:10.3390/v2112509 · Cited by 146
Chemical Genomic Profiling for Antimalarial Therapies, Response Signatures, and Molecular Targets
Yuan, J., Cheng, K. C.-C., Johnson, R. L., Huang, R., Pattaradilokrat, S., Liu, A., Guha, R., Fidock, D. A., Inglese, J., Wellems, T. E., et al. (2011) · Science · doi:10.1126/science.1205216 · Cited by 142
Lewandowicz, A., Tyler, P. C., Evans, G. B., Furneaux, R. H., & Schramm, V. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300259200 · Cited by 124
PS-15: a Potent, Orally Active Antimalarial from a New Class of Folic Acid Antagonists
Canfield, C. J., Milhous, W. K., Ager, A. L., Rossan, R. N., Sweeney, T. R., Lewis, N. J., & Jacobus, D. P. (1993) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1993.49.121 · Cited by 124
Artemisinin resistance—the clock is ticking
White, N. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61963-0 · Cited by 103
Thermodynamic dissection of the binding energetics of KNI‐272, a potent HIV‐1 protease inhibitor
Velázquez‐Campoy, A., Luque, I., Todd, M. J., Milutinovich, M., Kiso, Y., & Freire, E. (2000) · Protein Science · doi:10.1110/ps.9.9.1801 · Cited by 99
Tarnchompoo, B., Sirichaiwat, C., Phupong, W., Intaraudom, C., Worachart Sirawaraporn, A., Kamchonwongpaisan, S., Vanichtanankul, J., Thebtaranonth, Y., & Yuthavong, Y. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010131q · Cited by 98
Self-citationIncreased permeability of the malaria-infected erythrocyte to organic cations
Staines, H. M., Rae, C. D., & Kirk, K. (2000) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00187-x · Cited by 75
Nalam, M. N. L., & Schiffer, C. A. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283136cee · Cited by 58
Kamchonwongpaisan, S., Vanichtanankul, J., Tarnchompoo, B., Yuvaniyama, J., Taweechai, S., & Yuthavong, Y. (2005) · Analytical Chemistry · doi:10.1021/ac0487597 · Cited by 24
Self-citationMethotrexate: historical aspects
Bertino, J. R. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8452-5_1 · Cited by 6
Cited by
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 649
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic
Blasco, B., Leroy, D., & Fidock, D. A. (2017) · Nature Medicine · doi:10.1038/nm.4381 · Cited by 576
The past, present and future of anti-malarial medicines
Tse, E. G., Korsik, M., & Todd, M. H. (2019) · Malaria Journal · doi:10.1186/s12936-019-2724-z · Cited by 471
Malaria medicines: a glass half full?
Wells, T. N. C., van Huijsduijnen, R. H., & Van Voorhis, W. C. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4573 · Cited by 430
Phillips, M. A., Lotharius, J., Marsh, K., White, J., Dayan, A., White, K. L., Njoroge, J. W., El Mazouni, F., Lao, Y., Kokkonda, S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa6645 · Cited by 371
Self-citation
Metadata
- Authors
- Yuthavong, Y., Tarnchompoo, B., Vilaivan, T., Chitnumsub, P., Kamchonwongpaisan, S., Charman, S. A., McLennan, D. N., White, K. L., Vivas, L., Bongard, E., Thongphanchang, C., Taweechai, S., Vanichtanankul, J., Rattanajak, R., Arwon, U., Fantauzzi, P., Yuvaniyama, J., Charman, W. N., & Matthews, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-10-03
- Volume
- 109
- Issue
- 42
- Pages
- 16823-16828
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2057089852
- Cited by
- 277
- References
- 33
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.